Results 21 to 30 of about 1,008 (88)

Toxicity and Tolerability of ¹⁷⁷Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin - A Phase 2 Registry Study. [PDF]

Curr Radiopharm, 2022
Khatami A, Sistani G, Sutherland DEK, DeBrabandere S, Reid RH, Laidley DT.   +5 more
europepmc   +1 more source

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on ^99mTc-Octreotide and posttherapeutic ¹⁷⁷Lu-DOTA-TATE scans. [PDF]

World J Nucl Med, 2021
Amoui M, Ahmadi R, Qutbi M, Asli IN.
europepmc   +1 more source

Lutetium [¹⁷⁷Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study. [PDF]

Eur J Nucl Med Mol Imaging
Lastoria S, Rodari M, Sansovini M, Baldari S, D'Agostini A, Cervino AR, Filice A, Salgarello M, Perotti G, Nieri A, Campana D, Pellerito RE, Pomposelli E, Gaudieri V, Storto G, Grana CM, Signore A, Boni G, Dondi F, Simontacchi G, Seregni E.   +20 more
europepmc   +1 more source

Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges. [PDF]

Front Pharmacol
Shi W, Zhang L, Feng X, Liu J, Li X, Dong X, Li-Ann Wong A, Chen X, Wang L, Goh BC.   +9 more
europepmc   +1 more source

Long-term toxicity of tandem radioligand therapy using [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTA-TATE in neuroendocrine tumors: a polish multicenter experience with 20-year follow-up. [PDF]

Eur J Nucl Med Mol Imaging
Kołodziej M, Zemczak A, Pełka K, Pawlak D, Jóźwik-Plebanek K, Kamiński G, Kos-Kudła B, Królicki L, Saracyn M, Kunikowska J.   +9 more
europepmc   +1 more source

Estimation of split renal function on PET using the SSTR-targeting radioligands [¹⁸F]SiTATE, [⁶⁸Ga]Ga-DOTA-TATE and [⁶⁸Ga]Ga-DOTA-TOC in a theranostic setting. [PDF]

Eur J Nucl Med Mol Imaging
Tiling M, Unterrainer LM, Siegmund SC, Zahner J, Ells Z, Gildehaus FJ, Sheikh GT, Unterrainer M, Klimek K, Zacherl MJ, Böning G, Werner RA, Delker A, Holzgreve A.   +13 more
europepmc   +1 more source

A sstR2-targeted radiohybrid theranostic agent for PET imaging and β^- therapy with excellent preclinical performance. [PDF]

Npj Imaging
Deiser S, Fenzl S, König V, Inoue S, Casini A.   +4 more
europepmc   +1 more source

Improved patient models for simulation of clinically realistic ⁶⁸Ga-SSTR PET and ¹⁷⁷Lu-PRRT SPECT studies. [PDF]

EJNMMI Phys
Gustafsson J, Kalaitzidis P, Curkic Kapidzic S, Ljungberg M, Sjögreen Gleisner K.   +4 more
europepmc   +1 more source

Selective Chemistry Enables Simultaneous ImmunoPET and Radioimmunotherapy with a Dual-Labeled Probe. [PDF]

JACS Au
Kao WM, Grimaldi C, Samuels ZV, Dehlavi G, Strugala E, Cornejo M, Sebastiano J, Carter LM, Zeglis BM.   +8 more
europepmc   +1 more source

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE. [PDF]

EJNMMI Res
Liu F, Yang H, Zhang J, Li J, Qiao Y, Chen J, Song S.   +6 more
europepmc   +1 more source